Sydney Catalyst Boast & Toast



Sydney Catalyst Boast & Toast is an initiative to highlight the amazing work being done by our members. Big or small, we love hearing about the milestones and achievements in your translational cancer research.

Each month, one submission is included in the Sydney Catalyst eNewsletter, and all submissions are published on the Sydney Catalyst website. Every six months we review all of the submissions received and one member is awarded a prize of $2,500 to spend on research, travel or education.


So if you have started a new piece of work, hit a milestone, completed recruitment, been published, or received an award, we would love to hear about it. To enter, please complete this template and email it to us at


We hope this will be a great chance to get word of your research out to other Sydney Catalyst members, and potentially more widely, and to increase opportunities for collaboration.


Below are our Boast & Toast entries and round winners to date.

Round 6: September 2016

Winning Submission in Round 6:

Melanoma translational research achievementsCaroline Watts and Mbathio Dieng, Cancer Epidemiology and Prevention Research University of Sydney

Pilot and definitive randomised double-blind placebo- controlled trials evaluating an oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy induced nausea and vomiting: The CannabisCINV study, Nicole Wong, NHMRC CTC.

Melanoma model development and role of CD4 T cells and B cells in cancerHelen McGuire on behalf of T cell Biology Program, Centenary Institute

Supporting informed choice for management of screen detected Ductal Carcinoma in Situ (DCIS) among older women, Jolyn Hersch, Cancer Researchers, University of Sydney/ CeMPED

Collaborative Breast Cancer Research Program in Evidence Generation, Synthesis and Translation: Enhancing Breast Screening and Staging Research to Improve Practice, Nehmat Houssami, Sydney University Cancer Researchers/CRN

Round 5: March 2016

Winning Submission in Round 5: 

The transcription factor ELF5 drives anti-estrogen therapy resistance and metastasis in ER+ luminal breast cancer, David Gallego Ortega and Chris Ormandy, The Kinghorn Cancer Centre, Garvan Institute of Medical Research

Round 5 entries:

Targeting breast cancer metastasis: Delineating the role of "Perivascular macrophages" in tumour cell metastasis, Dr. Shweta Tikoo, Immune Imaging Program, Centenary Institute of Cancer Medicine and Cell Biology

Breast Translational Oncology Group & The Sydney Breast Cancer Foundation Tissue BankSandra O'Toole, RPAH/Garvan

MEOX1 and Haematopoietic Stem Cell InductionGeorgina Hollway, Garvan.


Round 4: September 2015

Winning Submission in Round 4:  

Novel silk-based drug carriers targeted for lung cancer, Sally Yunsun Kim, and Wojciech Chrzanowski on behalf of the Team (Kim, S.Y., Naskar, D., Kundu, S.C., Bishop, D.P., Doble, P.A., Boddy, A.V., Chan, H.K., Wall, I.B., Chrzanowski, W.Ch.)

Round 4 entries:

Starving Prostate Cancer Cells to Stop them from Growing, Associate Professor Jeff Holst, Origins of Cancer Program, Centenary Institute.

Anti-PD1 drugs in melanoma: Phase III trials in advanced melanoma, Associate Professor Georgina Long, Melanoma Institute Australia and The University of Sydney.

Personalised medicine for chemoresistant breast cancer through computational modelling, Dr David Croucher, The Kinghorn Cancer Centre, Garvan Institute of Medical Research.

Redefining the biophysical basis of MRI contrast in pre-treatment prostate cancer assessment, Aritrick Chatterjee, Dr Roger Bourne and team, Cancer Researchers, University of Sydney.

Spigelman classification of duodenal polyposis, Professor Allan Spigelman, The Kinghorn Cancer Centre/St Vincent's Hospital Sydney.

SOX9 regulates ERBB signalling in pancreatic cancer development, Andreia Pinho on behalf of Garvan's Pancreatic Tumourigenesis Lab.

Understanding skin cancer migration using 3D invasion systems, Nat Harris,The Kinghorn Cancer Centre, Garvan Insitute of Medical Research.


Round 3: March 2015

Winning Submission in Round 3: 

ClinTrial Refer: improving patient's access to clinical trials, Judith Trotman in collaboration with the Haematology Clinical Research Network, NSW.

Round 3 entries:

The MK2 kinase mediates enhanced inflammatory cytokine production in glioblastoma cells expressing the mutant EGFRvIII receptor, Fadi Gurgis and Dr Lenka Munoz, Cancer Researchers, University of Sydney.

Characterising the molecular function of Inhibitor of Differentiation 4 in poor prognosis basal-like breast cancer, Laura Baker, Dr Alexander Swarbrick, The Kinghorn Cancer Centre, Garvan Institute of Medical Research.

Imaging drivers of invasion & metastasis using nanotechnology, Paul Timpson & Heidi Welsh, Garvan Institute of Medical Research & Kinghorn Cancer Centre.

Rapid translation to clinical trial of a microRNA-based approach to the treatment of thoracic cancers, A/Prof Glen Reid and Prof Nico van Zandwijk, ADRI.

Genetic basis of hereditary colon cancer, Maija Kohonen-Corish, Kinghorn Cancer Centre.

Round 2: September 2014

Winning Submission in Round 2:

The dosimetry of low energy x-ray beams,Robin Hill,  Chris O'Brien Lifehouse

Round 2 entries:

Normalisation of blood vessels for control of tumor growth: role of a miRNA vascular permeability operon, Jia Li, Vascular Biology Program, Centenary Institute.

Cancer cachexia and tumorkines, Graham Robertson, Kinghorn/Garvan.

TOPGEAR - A randomised phase II/III trial of preoperative chemoradiotherapy versus preoperative chemotherapy for resectable gastric cancer, Danielle Miller, NHMRC Clinical Trials Centre

Evaluation of a web-based cognitive rehabilitation programme in cancer survivors with self-reported cognitive impairment, Victoria Bray, Haryana Dhillon, Janette Vardy, entre for Medical Psychology & Evidence-based Decision-making, USyd

Assess the ability of microRNA markers in plasma to predict for docetaxel resistance in men with castration-resistant prostate cancer, Dr Hui-Ming Lin, Assoc Prof Lisa Horvath et al.

From functional genomics to precision medicine: The therapeutic potential of targeting Rho/ROCK signalling in pancreatic cancer, Dr Marina Pajic, Personalised Cancer Therapeutics Group, The Kinghorn Cancer Centre.

Magnetic resonance diffusion microimaging of prostate and breast tissue, Drs Roger Bourne, Geoff Watson, Paul Sved and team, Sydney Uni Cancer Researchers.

Round 1: March 2014

Winning Submission in Round 1: 

The dark side of Sirtuin 1 in Pancreatic Cancer, Ilse Rooman of The Kinghorn Cancer Centre.

Round 1 entries: 

The evolution of hepatocellular carcinoma, Dr. Thomas Tu et al, Centenary Institute

e-TC: Development and phase I testing of a web-based intervention to reduce anxiety and depression in survivors of testicular cancer, Dr Louise Heiniger et al of Psycho-oncology Co-operative Research Group (PoCoG).

Translating evidence into practice: Implementing clinical pathways to relieve psychological distress and improve wellbeing for cancer patients, Dr Joanne Shaw et al, PoCoG/CemPED.

Lifehouse Opening, Prof. Michael Boyer, The Chris O'Brien Lifehouse

Investigation of Genetic, Environmental and Lifestyle Risk Factors to Improve Cancer Prevention and Cancer Survivorship Outcomes, Dr. Anne Cust, Cancer Epidemiology and Services Research.